No evidence of subclinical axial involvement seen in skin psoriasisSeptember 28, 2018Psoriatic ArthritisPsoriasis
Novel oral agent shows unprecedented efficacy in psoriasisSeptember 19, 2018PsoriasisPsoriatic Arthritis
Infliximab biosimilar only moderately less expensive in Medicare Part DSeptember 6, 2018Psoriatic ArthritisPsoriasis
Risankizumab proves more effective in psoriasis than ustekinumabAugust 28, 2018PsoriasisPsoriatic Arthritis
Psoriasis registry study provides more data on infliximab’s infection riskAugust 16, 2018PsoriasisPsoriatic Arthritis
FDA announces plan for biosimilar innovation and competitionJuly 19, 2018PsoriasisPsoriatic Arthritis
Elderly patients with psoriasis can benefit from biologics with low rates of adverse eventsJune 29, 2018Psoriatic ArthritisPsoriasis
Psoriasis therapy with biologics not linked to increased cancer riskMay 30, 2018PsoriasisPsoriatic Arthritis
